Jessica Söderfjord was only 54 years old when she received her Alzheimer's diagnosis, which she described as devastating and life-altering. As she advocates for Swedish patients in the early stages of the disease to gain access to new medications approved in the EU, she highlights the often overlooked and marginalized position of younger Alzheimer's patients. These individuals are frequently deprioritized in favor of older patients, despite their significant need for treatment.

The European Medicines Agency (EMA) granted approval last year for the first Alzheimer's medications that effectively reduce amyloid plaques in the brain, a hallmark of the disease. However, it remains uncertain when—or if—these effective treatments will be made available in Sweden. Söderfjord’s personal experience of battling not only Alzheimer's but also mental health issues, such as burnout and ADHD, underscores the complexity of living with multiple health conditions and the urgent need for improved healthcare responses.

As Söderfjord pushes for more attention and resources allocated to younger patients, her story raises broader questions about the healthcare system's ability to respond to the needs of diverse demographic groups. The ongoing delay in accessing new treatments reinforces concerns about inequality in healthcare, highlighting the necessity for more inclusive policies that ensure timely treatment for all affected by this debilitating disease.